TScan Therapeutics, Inc. (TCRX) Financials

TCRX Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 171.5 million 102.4 million
March 31, 2026 202.0 million 105.1 million
Dec. 31, 2025 228.8 million 105.7 million
Sept. 30, 2025 262.2 million 118.2 million

TCRX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -28.0 million 2.4 million
March 31, 2026 -24.3 million 2.5 million
Dec. 31, 2025 -32.2 million 2.0 million
Sept. 30, 2025 -33.9 million 3.0 million

TCRX Net Income

No data available :(

TCRX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 100.2 million 21.1 million 58.1 million
March 31, 2026 128.1 million 32.7 million 59.9 million
Dec. 31, 2025 152.4 million 32.5 million 61.6 million
Sept. 30, 2025 184.5 million 32.4 million 56.3 million

TCRX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 129.9 million
March 31, 2026 129.9 million
Dec. 31, 2025 129.9 million
Sept. 30, 2025 129.8 million

TCRX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 493000 23.4 million 8.1 million -
March 31, 2026 70000 21.9 million 8.2 million -
Dec. 31, 2025 171000 20.0 million 5.7 million -
Sept. 30, 2025 1.4 million 31.7 million 7.7 million -

TCRX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 1.1 million -
March 31, 2026 982000 693000
Dec. 31, 2025 2.6 million 723000
Sept. 30, 2025 2.5 million 767000

TCRX Revenue by Segment
Graph available only for paid members. Upgrade to see it.

TCRX

Price: $0.75

52 week price:
0.72
2.57

Earnings Per Share: -0.90 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 133500

Market Capitalization: 52.8 million

Links: